566 related articles for article (PubMed ID: 11533070)
1. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D; Jäger E; Knuth A
J Clin Pathol; 2001 Sep; 54(9):669-74. PubMed ID: 11533070
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy in clinical oncology.
Knuth A; Jäger D; Jäger E
Cancer Chemother Pharmacol; 2000; 46 Suppl():S46-51. PubMed ID: 10950148
[TBL] [Abstract][Full Text] [Related]
3. Peptide Vaccination in Clinical Oncology.
Jäger E; Jäger D; Knuth A
Onkologie; 2000 Oct; 23(5):410-415. PubMed ID: 11441234
[TBL] [Abstract][Full Text] [Related]
4. Strategies for the development of vaccines to treat breast cancer.
Jäger E; Jäger D; Knuth A
Recent Results Cancer Res; 1998; 152():94-102. PubMed ID: 9928550
[TBL] [Abstract][Full Text] [Related]
5. Vaccination for malignant melanoma: recent developments.
Jäger D; Jäger E; Knuth A
Oncology; 2001; 60(1):1-7. PubMed ID: 11150901
[TBL] [Abstract][Full Text] [Related]
6. CTL-defined cancer vaccines: perspectives for active immunotherapeutic interventions in minimal residual disease.
Jäger E; Jäger D; Knuth A
Cancer Metastasis Rev; 1999; 18(1):143-50. PubMed ID: 10505552
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes.
Jäger E; Chen YT; Drijfhout JW; Karbach J; Ringhoffer M; Jäger D; Arand M; Wada H; Noguchi Y; Stockert E; Old LJ; Knuth A
J Exp Med; 1998 Jan; 187(2):265-70. PubMed ID: 9432985
[TBL] [Abstract][Full Text] [Related]
8. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
9. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51.
Jäger E; Karbach J; Gnjatic S; Jäger D; Maeurer M; Atmaca A; Arand M; Skipper J; Stockert E; Chen YT; Old LJ; Knuth A
Cancer Immun; 2002 Sep; 2():12. PubMed ID: 12747757
[TBL] [Abstract][Full Text] [Related]
10. Cancer-testis antigens: promising targets for antigen directed antineoplastic immunotherapy.
Bodey B
Expert Opin Biol Ther; 2002 Aug; 2(6):577-84. PubMed ID: 12171503
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing Tumors.
Bioley G; Guillaume P; Luescher I; Bhardwaj N; Mears G; Old L; Valmori D; Ayyoub M
J Immunother; 2009; 32(2):161-8. PubMed ID: 19238015
[TBL] [Abstract][Full Text] [Related]
12. LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
Bender A; Karbach J; Neumann A; Jäger D; Al-Batran SE; Atmaca A; Weidmann E; Biskamp M; Gnjatic S; Pan L; Hoffman E; Old LJ; Knuth A; Jäger E
Cancer Immun; 2007 Oct; 7():16. PubMed ID: 17944437
[TBL] [Abstract][Full Text] [Related]
13. NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.
Thomas R; Al-Khadairi G; Roelands J; Hendrickx W; Dermime S; Bedognetti D; Decock J
Front Immunol; 2018; 9():947. PubMed ID: 29770138
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy II: Antigens, receptors and costimulation.
Searle PF; Young LS
Cancer Metastasis Rev; 1996 Sep; 15(3):329-49. PubMed ID: 9034595
[TBL] [Abstract][Full Text] [Related]
15. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.
Jäger E; Gnjatic S; Nagata Y; Stockert E; Jäger D; Karbach J; Neumann A; Rieckenberg J; Chen YT; Ritter G; Hoffman E; Arand M; Old LJ; Knuth A
Proc Natl Acad Sci U S A; 2000 Oct; 97(22):12198-203. PubMed ID: 11027314
[TBL] [Abstract][Full Text] [Related]
16. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments.
Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C
Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308
[TBL] [Abstract][Full Text] [Related]
17. Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro.
Mohamed YS; Dunnion D; Teobald I; Walewska R; Browning MJ
Immunobiology; 2012 Jul; 217(7):719-29. PubMed ID: 22305004
[TBL] [Abstract][Full Text] [Related]
18. HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccine.
Bioley G; Guillaume P; Luescher I; Yeh A; Dupont B; Bhardwaj N; Mears G; Old LJ; Valmori D; Ayyoub M
Clin Cancer Res; 2009 Jan; 15(1):299-306. PubMed ID: 19118058
[TBL] [Abstract][Full Text] [Related]
19. Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cells.
Muraoka D; Nishikawa H; Noguchi T; Wang L; Harada N; Sato E; Luescher I; Nakayama E; Kato T; Shiku H
Vaccine; 2013 Apr; 31(17):2110-8. PubMed ID: 23499606
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients.
Valmori D; Dutoit V; Liénard D; Rimoldi D; Pittet MJ; Champagne P; Ellefsen K; Sahin U; Speiser D; Lejeune F; Cerottini JC; Romero P
Cancer Res; 2000 Aug; 60(16):4499-506. PubMed ID: 10969798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
